Drug Profile
Alzheimer's disease neprilysin gene therapy
Alternative Names: Alzheimer's disease gene therapy; Lenti-NepLatest Information Update: 11 Dec 2007
Price :
$50
*
At a glance
- Originator Salk Institute; University of California, San Diego; University of Kentucky
- Class Antidementias; Gene therapies; Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease